This review provides a comprehensive overview of the diagnostic workup for pleural effusions, highlighting the role of specific biomarkers and the stepwise use of invasive procedures.
Answers are grounded in this paper and cite their sources.
May guide stepwise pleural effusion evaluation; leaves open prospective validation of biomarker thresholds.
Pleural effusions arise from a variety of systemic, inflammatory, infectious and malignant conditions. Their precise etiological diagnosis depends on a combination of medical history, physical examination, imaging tests and pertinent pleural fluid analyses; including specific biomarkers (e.g., natriuretic peptides for heart failure, adenosine deaminase for tuberculosis, or mesothelin for mesothelioma). Invasive procedures, such as pleuroscopic biopsies, may be required for persistently symptomatic effusions which remain undiagnosed after the analysis of one or more pleural fluid samples. However, whenever parietal pleural nodularity or thickening exist, image-guided biopsies should first be attempted. This review addresses the current diagnostic approach to pleural effusions secondary to heart failure, pneumonia, cancer, tuberculosis and other less frequent conditions.
No takes yet. Share an insight, caveat, or question.
Porcel et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: